-
Neos Therapeutics (NEOS): ADHD Approval Just In Time For Back To School - BMO
-
BMO Capital Reiterates Outperform Rating and $15 PT on Neos Therapeutics (NEOS); 'Steady Growth in Adzenys XR-ODT'
-
Neos Therapeutics Announces Pricing of Underwritten Public Offering of $25.0 Million of Common Stock
-
Neos Therapeutics (NEOS) to Offer Common Stock
-
Neos Therapeutics Announces Proposed Offering of Common Stock
-
Neos Therapeutics (NEOS): Thoughts After Management Meetings - BMO
-
BMO Capital Starts Neos Therapeutics (NEOS) at Outperform
-
BMO Capital Starts Neos Therapeutics (NEOS) at Outperform
-
Neos Therapeutics Announces Closing of Initial Public Offering and Exercise of Underwriters’ Over-Allotment Option
-
Neos Therapeutics (NEOS) IPO Opens 21% Higher
-
Neos Therapeutics (NEOS) Prices 4.8M Common Stock IPO at $15/Share, at Middle of Range
-
Neos Therapeutics Announces Pricing of Initial Public Offering

